Cojocaru Alexandru, Zavaleanu Alexandra Daniela, Călina Daniela Cornelia, Gheonea Dan Ionut, Osiac Eugen, Boboc Ianis Kevyn Stefan, Mitran Smaranda Ioana
Department of Physiology, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Experimental Research Center for Normal and Pathological Aging,University of Medicine and Pharmacy of Craiova, Romania.
Curr Health Sci J. 2021 Apr-Jun;47(2):263-269. doi: 10.12865/CHSJ.47.02.17. Epub 2021 Jun 30.
Dementias are the third cause of the disability-adjusted life-years (DALYs) worldwide with Alzheimer's (AD) having the highest prevalence. Despite ample research in the field, therapeutic options are limited. However, with the increase in lifespan, a larger number of AD patients will receive other medication for the evermore-increased number of comorbidities that such patients face. The purpose of this study was to evaluate the neurological and cardiac effects of verapamil, on C57BL/6J-TgN (Thy1-APPKM670/671NL; Thy1-PS1L166P (APP) mice. The daily administration of 3.5mg/kg of verapamil for 28 days revealed different effects on young and aged APP mice. While young animals showed less anxiety and improved short-term memory with minimal cardiac effects (an increase in the duration of ventricular depolarization), aged ones did not present behavioral improvements, but with a decrease in the duration of ventricular depolarizing. Repolarization effects of verapamil were similar in young and aged animals, except for the duration of the ST segment that was longer in aged animals. Considering our results, the use of calcium blockers in AD patients should take into consideration the stage of the disease, as different effects could be seen at different stages of AD, in our model.
痴呆症是全球伤残调整生命年（DALYs）的第三大病因，其中阿尔茨海默病（AD）的患病率最高。尽管该领域已有大量研究，但治疗选择仍然有限。然而，随着寿命的延长，越来越多的AD患者将因面临的合并症数量不断增加而接受其他药物治疗。本研究的目的是评估维拉帕米对C57BL/6J-TgN（Thy1-APPKM670/671NL；Thy1-PS1L166P（APP）小鼠的神经和心脏影响。每天给予3.5mg/kg维拉帕米，持续28天，结果显示对年轻和老年APP小鼠有不同影响。虽然年轻动物表现出较少的焦虑，短期记忆得到改善，心脏影响最小（心室去极化持续时间增加），但老年动物没有行为改善，而是心室去极化持续时间减少。维拉帕米的复极化作用在年轻和老年动物中相似，但老年动物的ST段持续时间更长。考虑到我们的研究结果，在AD患者中使用钙阻滞剂应考虑疾病阶段，因为在我们的模型中，AD的不同阶段可能会出现不同的影响。
